In late 2019, a novel infectious disease with human to human transmission was identified in Wuhan China, which now has turned into a global pandemic. Countries all over the world has implemented some sort of lockdown to slow down its infection and mitigate it.Lockdown due to COVID-19 has drastic effects on social and economic fronts. However, this lockdown also have some positive effect on natural environment. Recent data released by NASA (National Aeronautics and Space Administration) and ESA (European Space Agency) indicates that pollution in some of the epicenters of Italy, Spain and USA etc. has reduced up to 30%. This study compiled the environmental data released by NASA and ESA before and after the coronavirus pandemic and discuss its impact on environmental quality.

Late in 2020, two genetically-distinct clusters of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with mutations of biological concern were reported, one in the United Kingdom and one in South Africa. Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2). We account for potential biases in genomic surveillance efforts by including passenger volumes from location of where the lineage was first reported, London and South Africa respectively. Using the software tool grinch (global report investigating novel coronavirus haplotypes), we track the international spread of lineages of concern with automated daily reports, Further, we have built a custom tracking website (cov-lineages.org/global_report.html) which hosts this daily report and will continue to include novel SARS-CoV-2 lineages of concern as they are detected.

Late in 2020, two genetically-distinct clusters of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with mutations of biological concern were reported, one in the United Kingdom and one in South Africa. Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2). We account for potential biases in genomic surveillance efforts by including passenger volumes from location of where the lineage was first reported, London and South Africa respectively. Using the software tool grinch (global report investigating novel coronavirus haplotypes), we track the international spread of lineages of concern with automated daily reports, Further, we have built a custom tracking website (cov-lineages.org/global_report.html) which hosts this daily report and will continue to include novel SARS-CoV-2 lineages of concern as they are detected.

Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.

In recent years, ginger has become a subject of interest because of its beneficial effects on human health. The purpose of the present study was to investigate the effects of daily oral administration of ginger extract for 6 weeks on plasma glucose, lipid profile and kidney functions in alloxan-induced diabetic rats to show the ameliorating and partly curative effects in alloxan induced-diabetic rats (150 mg/kg i.p.(Intrapretonial). Rats (130-150gm) were divided into 4 groups; normal control rats, diabetic control rats, diabetic rats post-treated with ginger and diabetic rats pretreated with ginger. Ginger extract was administered orally for 6 weeks to post-treated and pre-treated rats, and they were compared with the normal and diabetic groups, respectively. Plasma glucose was reduced significantly in both post-treated and pretreated groups. The post-treatment with ginger extract reduced plasma cholesterol, triglyceride and LDL-cholesterol, but during the pre-treatment with ginger extract produced insignificant change only in plasma triglyceride level. The plasma HDLcholesterol was significantly increased in post-treated and pre-treated groups. The plasma creatinine, urea and uric acid levels were significantly reduced in post-treated group; also in pre-treated group, they were reduced but urea level statistically did not change. It is concluded that the consumption of ginger produced a significant hypoglycemic effect in diabetic rats. In addition, ginger is capable of improving hyperlipidemia and the impaired kidney functions in alloxan-induced diabetic rats.